Becton Dickinson said this week that it has received clearance from the US Food and Drug Administration to market the BD Max Cdiff assay. The assay is performed on the fully automated BD Max system and is designed to rapidly and accurately detect the toxin B gene in patients suspected of Clostridium difficile infection.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.